Statin Carcinogenicity Data Could Be Reviewed By California In 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
The state's Office of Environmental Health Hazard Assessment has received data on nearly all the drugs, including previously unpublished information. Requests to FDA have largely gone unanswered.
You may also be interested in...
Calif. Prop 65 Warnings On Smoking Cessation Drugs Federally Preempted, Court Says
State-mandated warnings that OTC nicotine replacement therapies may "cause reproductive harm" directly conflict with FDA labeling requirements, California Supreme Court rules in a victory for drug manufacturers and the agency.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles